Vimarsana
Biggest News Aggregation in the World

Page 8 - Precigen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Precigen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Precigen Today - Breaking & Trending Today

Precigen, Inc. (NASDAQ:PGEN) Shares Acquired by The Manufacturers Life Insurance Company - Vimarsana News

Precigen, Inc. (NASDAQ:PGEN) Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its holdings in shares of Precigen, Inc. (NASDAQ:PGEN – Get Rating) by 96.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,234 shares of the biotechnology company’s stock after purchasing an additional 21,269 shares […]

Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting - Vimarsana News

Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023 - Vimarsana News

Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023

– First preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR) – – MSLN is...

Precigen : Material Agreement - Form 8-K - Vimarsana News

Precigen : Material Agreement - Form 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT ... | April 5, 2023

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® - Vimarsana News

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...